Yimitasvir - HEC Pharm

Drug Profile

Yimitasvir - HEC Pharm

Alternative Names: DAG 181; Yimitasvir phosphate

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HEC Pharm
  • Developer Dongguan HEC TaiGen Biopharmaceuticals; HEC Pharm
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in China (PO, Capsule)
  • 15 May 2018 Sunshine Lake PharmaSunshine Lake Pharma completes enrolment in a phase I trial for Healthy volunteers in China (ChiCTR1800016384)
  • 03 Apr 2018 Sunshine Lake Pharma plans a phase III trial for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in China (NCT03487107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top